Gut-brain axis through the lens of gut microbiota and their relationships with Alzheimer's disease pathology: Review and recommendations
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is a neurodegenerative disorder that affects millions of people worldwide. Growing evidence suggests that the gut microbiome (GM) plays a pivotal role in the pathogenesis of AD through the microbiota-gut-brain axis (MGB). Alterations in GM composition and diversity have been observed in both animal models and in human patients with AD. GM dysbiosis has been implicated in increased intestinal permeability, blood-brain barrier (BBB) impairment, neuroinflammation and the development of hallmarks of AD. Further elucidation of the role of GM in AD could pave way for the development of holistic predictive methods for determining AD risk and progression of disease. Furthermore, accumulating evidence suggests that GM modulation could alleviate adverse symptoms of AD or serve as a preventive measure. In addition, increasing evidence shows that Type 2 Diabetes Mellitus (T2DM) is often comorbid with AD, with common GM alterations and inflammatory response, which could chart the development of GM-related treatment interventions for both diseases. We conclude by exploring the therapeutic potential of GM in alleviating symptoms of AD and in reducing risk. Furthermore, we also propose future directions in AD research, namely fecal microbiota transplantation (FMT) and precision medicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nichols, E., Steinmetz, J. D., Vollset, S. E., Fukutaki, K., Chalek, J., Abd-Allah, F., Abdoli, A., Abualhasan, A., Abu-Gharbieh, E., Akram, T. T., et al. (2022) · The Lancet Public Health · doi:10.1016/s2468-2667(21)00249-8 · Cited by 5,575
Blennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134
Bloom (2014) · doi:10.1001/jamaneurol.2013.5847 · Cited by 2,194
Risk of dementia in diabetes mellitus: a systematic review
Biessels, G. J., Staekenborg, S., Brunner, E., Brayne, C., & Scheltens, P. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70284-2 · Cited by 2,187 · cited 2×
“Several studies also found that in comparison to healthy controls, patients with T2DM had lower cognitive performance in all cognitive domains, suggesting a crucial link between accelerated cognitive decline and T2DM (Biessels et al., 2006; Fontbonne et al., 2001; Geijselaers et al., 2017).”
BackgroundResultA/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Feldman, H. H., Frisoni, G. B., Hampel, H., Jagust, W. J., Johnson, K. A., Knopman, D. S., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002923 · Cited by 1,864
Regulation of inflammation by short chain fatty acids
Vinolo, M. A. R., Rodrigues, H. G., Nachbar, R. T., & Curi, R. (2011) · Nutrients · doi:10.3390/nu3100858 · Cited by 1,724
The vagus nerve at the interface of the microbiota-gut-brain axis
Bonaz, B., Bazin, T., & Pellissier, S. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00049 · Cited by 1,397
Cattaneo, A., Cattane, N., Galluzzi, S., Provasi, S., Lopizzo, N., Festari, C., Ferrari, C., Guerra, U. P., Paghera, B., Muscio, C., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.08.019 · Cited by 1,382
Alzheimer’s disease: pathogenesis, diagnostics, and therapeutics
Tiwari, S., Atluri, V., Kaushik, A., Yndart, A., & Nair, M. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s200490 · Cited by 1,308
Alzheimer’s disease is type 3 diabetes—Evidence reviewed
de la Monte, S. M., & Wands, J. R. (2008) · Journal of Diabetes Science and Technology · doi:10.1177/193229680800200619 · Cited by 1,158
Wang, X., Sun, G., Feng, T., Zhang, J., Huang, X., Wang, T., Xie, Z., Chu, X., Yang, J., Wang, H., et al. (2019) · Cell Research · doi:10.1038/s41422-019-0216-x · Cited by 1,144 · cited 2×
“Like diet modifications, pro- and prebiotic supplementation can improve intestinal integrity, reversing “leaky-gut”, reducing the translocation of harmful neuromodulators, reducing neuroinflammation (Wang et al., 2019).”
BackgroundThe microbiome-gut-brain axis in health and disease
Dinan, T. G., & Cryan, J. F. (2017) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2016.09.007 · Cited by 1,111
Cheng, G., Huang, C., Deng, H., & Wang, H. (2012) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2012.02758.x · Cited by 1,040
Gut microbes and the brain: paradigm shift in neuroscience
Mayer, E. A., Knight, R., Mazmanian, S. K., Cryan, J. F., & Tillisch, K. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.3299-14.2014 · Cited by 1,033
Disease-associated astrocytes in Alzheimer’s disease and aging
Habib, N., McCabe, C., Medina, S., Varshavsky, M., Kitsberg, D., Dvir-Szternfeld, R., Green, G., Dionne, D., Nguyen, L., Marshall, J. L., et al. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-0624-8 · Cited by 1,009
Ghosh, T. S., Rampelli, S., Jeffery, I. B., Santoro, A., Neto, M., Capri, M., Giampieri, E., Jennings, A., Candela, M., Turroni, S., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-319654 · Cited by 991
Increased Risk of Type 2 Diabetes in Alzheimer Disease
Janson, J., Laedtke, T., Parisi, J. E., O’Brien, P., Petersen, R. C., & Butler, P. C. (2004) · Diabetes · doi:10.2337/diabetes.53.2.474 · Cited by 950 · cited 2×
“This can result in key hallmarks, such as insulin resistance in T2DM (Carranza-Naval et al., 2021; Janson et al., 2004; Marseglia et al., 2019).”
BackgroundReduction of Abeta amyloid pathology in APPPS1 transgenic mice in the absence of gut microbiota
Harach, T., Marungruang, N., Duthilleul, N., Cheatham, V., Mc Coy, K. D., Frisoni, G., Neher, J. J., Fåk, F., Jucker, M., Lasser, T., et al. (2017) · Scientific Reports · doi:10.1038/srep41802 · Cited by 901
Brain-Gut-Microbiota Axis in Alzheimer’s Disease
Kowalski, K., & Mulak, A. (2019) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm18087 · Cited by 826
Alzheimer's disease: experimental models and reality
Drummond, E., & Wisniewski, T. (2017) · Acta Neuropathologica · doi:10.1007/s00401-016-1662-x · Cited by 810
Moloney, A. M., Griffin, R. J., Timmons, S., O’Connor, R., Ravid, R., & O’Neill, C. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.04.002 · Cited by 764 · cited 2×
“Decreased insulin-PI3K-AKT signaling is hypothesized to activate glycogen synthase kinase-3β, a major tau kinase, leading to tau phosphorylation and protein o-GlcNAcylation which could contribute to neurodegeneration (Moloney et al., 2010).”
BackgroundXue, M., Xu, W., Ou, Y.-N., Cao, X.-P., Tan, M.-S., Tan, L., & Yu, J.-T. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.100944 · Cited by 715
Lipopolysaccharide-induced neuroinflammation as a bridge to understand neurodegeneration
Batista, C. R. A., Gomes, G. F., Candelario-Jalil, E., Fiebich, B. L., & de Oliveira, A. C. P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092293 · Cited by 529
Gut microbiota and dysbiosis in Alzheimer's disease: Implications for pathogenesis and treatment
Liu, S., Gao, J., Zhu, M., Liu, K., & Zhang, H.-L. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02073-3 · Cited by 516 · cited 2×
“However, further research is needed to elucidate if VN stimulation or vagotomy could be a possible therapeutic intervention for AD, in the context of GM modulation (Liu et al., 2020).”
BackgroundChen, C., Liao, J., Xia, Y., Liu, X., Jones, R., Haran, J., McCormick, B., Sampson, T. R., Alam, A., & Ye, K. (2022) · Gut · doi:10.1136/gutjnl-2021-326269 · Cited by 491
The gut microbiota-derived metabolite trimethylamine N-oxide is elevated in Alzheimer’s disease
Vogt, N. M., Romano, K. A., Darst, B. F., Engelman, C. D., Johnson, S. C., Carlsson, C. M., Asthana, S., Blennow, K., Zetterberg, H., Bendlin, B. B., et al. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0451-2 · Cited by 471
Liu, C., Feng, X., Li, Q., Wang, Y., Li, Q., & Hua, M. (2016) · Cytokine · doi:10.1016/j.cyto.2016.06.028 · Cited by 470 · cited 1×
“…of short term and working memory in T2DM patients (similar to the effects of AD) through impaired gut microbial metabolism of aromatic amino acids (Carranza-Naval et al., 2021; Liu et al., 2016; Qin et al., 2012; Ramos-Rodriguez et al., 2015; Sankar et al., 2020; Sharma and Tripathi, 2019).”
BackgroundAltered Gut Microbiota in a Mouse Model of Alzheimer’s Disease
Zhang, L., Wang, Y., Xiayu, X., Shi, C., Chen, W., Song, N., Fu, X., Zhou, R., Xu, Y.-F., Huang, L., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170020 · Cited by 449
Diabetes in Midlife and Cognitive Change Over 20 Years: A Cohort Study
Rawlings, A. M., Sharrett, A. R., Schneider, A. L. C., Coresh, J., Albert, M., Couper, D., Griswold, M., Gottesman, R. F., Wagenknecht, L. E., Windham, B. G., et al. (2014) · Annals of Internal Medicine · doi:10.7326/m14-0737 · Cited by 447
Guo, J. L., Narasimhan, S., Changolkar, L., He, Z., Stieber, A., Zhang, B., Gathagan, R. J., Iba, M., McBride, J. D., Trojanowski, J. Q., et al. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20160833 · Cited by 440
A gut bacterial amyloid promotes α-synuclein aggregation and motor impairment in mice
Sampson, T. R., Challis, C., Jain, N., Moiseyenko, A., Ladinsky, M. S., Shastri, G. G., Thron, T., Needham, B. D., Horvath, I., Debelius, J. W., et al. (2020) · eLife · doi:10.7554/elife.53111 · Cited by 439
The progress of gut microbiome research related to brain disorders
Zhu, S., Jiang, Y., Xu, K., Cui, M., Ye, W., Zhao, G., Jin, L., & Chen, X. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-1705-z · Cited by 419 · cited 1×
“spurred the publication of more than 25,000 GM-related publications in the past five years, representing more than 80% of the overall GM publications since 1977 (Askarova et al., 2020; Cani, 2018; Zhu et al., 2020).”
BackgroundProbiotics modulate the microbiota-gut-brain axis and improve memory deficits in aged SAMP8 mice
Yang, X., Yu, D., Xue, L., Li, H., & Du, J. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.07.001 · Cited by 407
Govindarajan, N., Agis-Balboa, R. C., Walter, J., Sananbenesi, F., & Fischer, A. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-110080 · Cited by 405
Zhao, Y., Jaber, V., & Lukiw, W. J. (2017) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2017.00318 · Cited by 379
Ho, L., Ono, K., Tsuji, M., Mazzola, P., Singh, R., & Pasinetti, G. M. (2018) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2018.1400909 · Cited by 376
The Microbiota–Gut–Brain Axis and Alzheimer’s Disease: Neuroinflammation Is to Blame?
Megur, A., Baltriukienė, D., Bukelskienė, V., & Burokas, A. (2020) · Nutrients · doi:10.3390/nu13010037 · Cited by 323 · cited 8×
“leading to neuroinflammatory response and neurodegeneration (Megur et al., 2020).”
BackgroundInfluentialFontbonne, A., Berr, C., Ducimetière, P., & Alpérovitch, A. (2001) · Diabetes Care · doi:10.2337/diacare.24.2.366 · Cited by 297
Campbell, J. M., Stephenson, M. D., de Courten, B., Chapman, I., Bellman, S. M., & Aromataris, E. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180263 · Cited by 292
Alzheimer's disease and type 2 diabetes: a critical assessment of the shared pathological traits
Chatterjee, S., & Mudher, A. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00383 · Cited by 270 · cited 2×
“Particularly, dysregulation in inflammatory response, impaired insulin resistance, glucose and amyloid metabolism were identified in both T2DM and AD (Biessels et al., 2006; Chatterjee and Mudher, 2018; Cheng et al., 2012; Rawlings et al., 2014).”
BackgroundThe Impact of Disease Comorbidities in Alzheimer’s Disease
Santiago, J. A., & Potashkin, J. A. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.631770 · Cited by 259
Liu, Q., Xi, Y., Wang, Q., Liu, J., Li, P., Meng, X., Liu, K., Chen, W., Liu, X., & Liu, Z. (2021) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2021.04.005 · Cited by 241
Bäuerl, C., Collado, M. C., Diaz Cuevas, A., Viña, J., & Pérez Martínez, G. (2018) · Letters in Applied Microbiology · doi:10.1111/lam.12882 · Cited by 238
Chen, D., Yang, X., Yang, J., Lai, G., Yong, T., Tang, X., Shuai, O., Zhou, G., Xie, Y., & Wu, Q. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00403 · Cited by 227
The Potential Role of Gut Microbiota in Alzheimer’s Disease: From Diagnosis to Treatment
Varesi, A., Pierella, E., Romeo, M., Piccini, G. B., Alfano, C., Bjørklund, G., Oppong, A., Ricevuti, G., Esposito, C., Chirumbolo, S., et al. (2022) · Nutrients · doi:10.3390/nu14030668 · Cited by 225 · cited 8×
“Varesi et al., outlines the different studies that explored variations of the mediterranean and ketogenic diets (e.g. Dietary Approaches to Stop Hypertension (DASH), Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) diets) (Varesi et al., 2022b).”
BackgroundInfluentialMorris, G. P., Clark, I. A., & Vissel, B. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1918-8 · Cited by 212
The links between the gut microbiome, aging, modern lifestyle and Alzheimer's disease
Askarova, S., Umbayev, B., Masoud, A.-R., Kaiyrlykyzy, A., Safarova, Y., Tsoy, A., Olzhayev, F., & Kushugulova, A. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00104 · Cited by 208
Hazan, S. (2020) · Journal of International Medical Research · doi:10.1177/0300060520925930 · Cited by 200 · cited 21×
“This correlated with an improvement in cognitive function and increase in synaptic plasticity in Tg mice which was also observed in 5XFAD mice in a study by Holsinger et al., who reported an increase in SCFAs, positive alterations in gut microbiota, improvement in spatial and recognition memory and reduction in amyloi…”
BackgroundMethodInfluentialShabbir, U., Arshad, M. S., Sameen, A., & Oh, D.-H. (2021) · Nutrients · doi:10.3390/nu13020690 · Cited by 191 · cited 8×
“, stated that LPS plays a key role in the progression of neurodegeneration by activating microglia and astrocytes, along with neuroinflammatory response which leads to an increase in amyloid precursor protein, Aβ42 fibrillogenesis, plaque formation and subsequently neuronal loss (Figure 3(8)-(9)) (Batista et al., 2019…”
BackgroundInfluentialTargeting microglia for the treatment of Alzheimer’s Disease
Wes, P. D., Sayed, F. A., Bard, F., & Gan, L. (2016) · Glia · doi:10.1002/glia.22988 · Cited by 185
Dysbiosis, gut barrier dysfunction and inflammation in dementia: a pilot study
Stadlbauer, V., Engertsberger, L., Komarova, I., Feldbacher, N., Leber, B., Pichler, G., Fink, N., Scarpatetti, M., Schippinger, W., Schmidt, R., et al. (2020) · BMC Geriatrics · doi:10.1186/s12877-020-01644-2 · Cited by 182
Kahn, M. S., Kranjac, D., Alonzo, C. A., Haase, J. H., Cedillos, R. O., McLinden, K. A., Boehm, G. W., & Chumley, M. J. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.01.010 · Cited by 177
Kuan, Y.-C., Huang, K.-W., Lin, C.-L., Hu, C.-J., & Kao, C.-H. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.06.002 · Cited by 168
Blood-Brain Glucose Transfer in Alzheimer’s disease: Effect of GLP-1 Analog Treatment
Gejl, M., Brock, B., Egefjord, L., Vang, K., Rungby, J., & Gjedde, A. (2017) · Scientific Reports · doi:10.1038/s41598-017-17718-y · Cited by 163 · cited 2×
“Glucagon-like peptide-1 (GLP-1) agonists are another antidiabetic drug that has shown promise in improving cognitive function in AD preclinical models and lowered Aβ42 levels in extracellular vesicles in patients with AD, although not producing significant improvements in cognitive function or positive changes in CSF…”
BackgroundCarrero, I., Gonzalo, M. R., Martin, B., Sanz-Anquela, J. M., Arévalo-Serrano, J., & Gonzalo-Ruiz, A. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2012.05.004 · Cited by 132 · cited 2×
“their translocation via the GBA (Figure 3(6)) (Carrero et al., 2012).”
Sluggett, J. K., Koponen, M., Bell, J. S., Taipale, H., Tanskanen, A., Tiihonen, J., Uusitupa, M., Tolppanen, A.-M., & Hartikainen, S. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz234 · Cited by 95
The Role of the Microbiota-Gut-Brain Axis in the Development of Alzheimer’s Disease
Wiatrak, B., Balon, K., Jawień, P., Bednarz, D., Jęśkowiak, I., & Szeląg, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094862 · Cited by 58
Friedland, R. P., McMillan, J. D., & Kurlawala, Z. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051652 · Cited by 56
Cited by
Anti-Amyloid Therapies for Alzheimer’s Disease and the Amyloid Cascade Hypothesis
Fedele, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914499 · Cited by 102
The human microbiome in clinical translation: from bench to bedside
Bautista, J., Echeverría, C. E., Maldonado-Noboa, I., Ojeda-Mosquera, S., Hidalgo-Tinoco, C., & López-Cortés, A. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1632435 · Cited by 55
Høyer, K. L., Dahl Baunwall, S. M., Kornum, D. S., Klinge, M. W., Drewes, A. M., Yderstræde, K. B., Thingholm, L. B., Mortensen, M. S., Mikkelsen, S., Erikstrup, C., et al. (2025) · eClinicalMedicine · doi:10.1016/j.eclinm.2024.103000 · Cited by 13
Metadata
- Authors
- L., K., Ng, T. K. S., Wee, H. N., & Ching, J.
- Venue
- Mechanisms of Ageing and Development
- Publisher
- Elsevier BV
- Published
- 2023-04
- Volume
- 211
- Pages
- 111787
- ISSN
- 0047-6374 (ISSN-L)
- OpenAlex
- W4319215978
- Cited by
- 58
- References
- 58
- FWCI
- 4.33
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.